289 related articles for article (PubMed ID: 11587363)
21. The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
Lutterbach B; Sun D; Schuetz J; Hiebert SW
Mol Cell Biol; 1998 Jun; 18(6):3604-11. PubMed ID: 9584201
[TBL] [Abstract][Full Text] [Related]
22. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
23. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
24. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional repression by leukaemia-associated ETO family members can be independent of oligomerization and coexpressed hSIN3B and N-CoR.
Olsson A; Olsson I; Dhanda RS
Biochim Biophys Acta; 2008 Oct; 1779(10):590-8. PubMed ID: 18586123
[TBL] [Abstract][Full Text] [Related]
26. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
[TBL] [Abstract][Full Text] [Related]
27. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
28. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription.
Hiebert SW; Sun W; Davis JN; Golub T; Shurtleff S; Buijs A; Downing JR; Grosveld G; Roussell MF; Gilliland DG; Lenny N; Meyers S
Mol Cell Biol; 1996 Apr; 16(4):1349-55. PubMed ID: 8657108
[TBL] [Abstract][Full Text] [Related]
29. The ETO (MTG8) gene family.
Davis JN; McGhee L; Meyers S
Gene; 2003 Jan; 303():1-10. PubMed ID: 12559562
[TBL] [Abstract][Full Text] [Related]
30. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
31. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
32. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
33. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A.
Chakrabarti SR; Nucifora G
Biochem Biophys Res Commun; 1999 Nov; 264(3):871-7. PubMed ID: 10544023
[TBL] [Abstract][Full Text] [Related]
34. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
[TBL] [Abstract][Full Text] [Related]
35. AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.
Choi Y; Elagib KE; Goldfarb AN
Crit Rev Eukaryot Gene Expr; 2005; 15(3):207-16. PubMed ID: 16390317
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
[TBL] [Abstract][Full Text] [Related]
37. Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1.
Meyers S; Hiebert SW
Crit Rev Eukaryot Gene Expr; 1995; 5(3-4):365-83. PubMed ID: 8834231
[TBL] [Abstract][Full Text] [Related]
38. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR
Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706
[TBL] [Abstract][Full Text] [Related]
39. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.
Yang G; Khalaf W; van de Locht L; Jansen JH; van der Reijden BA; Müller-Tidow C; Delwel HR; Serve H; Clapp DW; Hiebert SW
Ann Hematol; 2004 Jun; 83(6):329-30. PubMed ID: 15052372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
